(Q38097748)

28 August 2017

title

Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature (English)

1 reference

28 August 2017

main subject

antisynthetase syndrome

1 reference

1 reference

Andrea Doria

8

0 references

Leonardo Punzi

object named as

Leonardo Punzi

7

0 references

Margherita Zen

3

object named as

Margherita Zen

1 reference

28 August 2017

Linda Nalotto

1

1 reference

28 August 2017

Luca Iaccarino

2

1 reference

28 August 2017

Mariele Gatto

4

1 reference

28 August 2017

Elisabetta Borella

5

1 reference

28 August 2017

Marta Domenighetti

6

1 reference

28 August 2017

publication date

1 July 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

56

1 reference

28 August 2017

issue

2-3

1 reference

28 August 2017

page(s)

362-370

1 reference

Polymyositis and dermatomyositis

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Polymyositis, dermatomyositis and inclusion-body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Inflammatory muscle diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Update on idiopathic inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Polymyositis, dermatomyositis and malignancy: a further intriguing link

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Myofiber stress-response in myositis: parallel investigations on patients and experimental animal models of muscle regeneration and systemic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Cutting edge issues in polymyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Polymyositis-dermatomyositis and infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Pregnancy in rare autoimmune rheumatic diseases: UCTD, MCTD, myositis, systemic vasculitis and Beçhet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Commercial blot assays in the diagnosis of systemic rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Clinical implications of autoantibody screening in patients with autoimmune myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Overlap connective tissue disease syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Rituximab in life threatening antisynthetase syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Therapy of polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Immunotherapy of myositis: issues, concerns and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Rituximab in the treatment of antisynthetase syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Rituximab treatment of the anti-synthetase syndrome: a retrospective case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Rituximab in the treatment of refractory dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Successful treatment of cardiac involvement in dermatomyositis with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Refractory dermatomyositis associated with chronic organizing pneumonia treated with rituximab: report of one case

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Rituximab treatment in patients with refractory inflammatory myopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

A gene expression approach to study perturbed pathways in myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

The role of jo-1 in the immunopathogenesis of polymyositis: Current hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Antinuclear antibodies in rheumatic disease: a proposal for a function-based classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Long-lived autoreactive plasma cells drive persistent autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

CD20-targeted therapy: the next generation of antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

FOXP3+ regulatory T cells in the human immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Role of regulatory T cells in a new mouse model of experimental autoimmune myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

FOXP3+ T regulatory cells in idiopathic inflammatory myopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8408-9

Resistant dermatomyositis complicated by tubercular myositis and successfully treated with rituximab

21 January 2018

1 reference

12 December 2020

[Evaluation of the effectiveness of treatment with rituximab associated to cyclophosphamide in patients with resistant idiopathic inflammatory myopathy]

1 reference

12 December 2020

Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases

1 reference

12 December 2020

Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy

1 reference

12 December 2020

Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients

1 reference

12 December 2020

Efficacy of rituximab in refractory polymyositis

1 reference

12 December 2020

Longlasting remissions after treatment with rituximab for autoimmune myositis

1 reference

12 December 2020

[Myositis specific and myositis associated autoantibodies in idiopathic inflammatory myopathies: a serologic study of 46 patients]

1 reference

12 December 2020

Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases

1 reference

12 December 2020

Rituximab as therapy for refractory polymyositis and dermatomyositis.

1 reference

12 December 2020

[Rare autoimmune rheumatic illnesses during pregnancy. Systemic sclerosis, polymyositis/dermatomyositis and vasculitis]

1 reference

12 December 2020

Rituximab restored the muscle power and rescued from a refractory fatal respiratory failure in a patient with elderly-onset polymyositis.

1 reference

12 December 2020

Dermatomyositis and polymyositis: new treatment targets on the horizon

1 reference

12 December 2020

Expression of myositis specific autoantigens during post-natal myogenesis

1 reference

12 December 2020

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis

1 reference

12 December 2020

Rituximab in the treatment of dermatomyositis: an open-label pilot study

1 reference

12 December 2020

Long-term remission of severe refractory dermatopolymyositis with a weekly-scheme of immunoglobulin followed by rituximab therapy

1 reference

12 December 2020

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab

1 reference

12 December 2020

Rituximab for refractory polymyositis: an open-label prospective study.

1 reference

12 December 2020

10.1007/S12026-013-8408-9

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1022348847

0 references

1 reference